



Teva Pharmaceutical Industries Ltd.

Web Site: [www.tevapharm.com](http://www.tevapharm.com)



Web Site: [www.ivax.com](http://www.ivax.com)

---

Contact: Dan Suesskind  
Chief Financial Officer  
Teva Pharmaceutical Industries Ltd.  
(011) 972-2-589-2840

George Barrett  
President and CEO  
Teva North America  
(215) 591-3030

Liraz Kalif / Kevin Mannix  
Investor Relations  
(011) 972-3-926-7554

Neil Flanzraich  
Vice Chairman and President  
IVAX Corporation  
(305) 575-6008

David Malina  
Vice President, Investor Relations  
and Corporate Communications  
IVAX Corporation  
(305) 575-6043

**FOR IMMEDIATE RELEASE**

**Teva and IVAX Issue Statement Regarding Elections by Holders  
of IVAX Convertible Notes**

**Jerusalem, Israel and Miami, Florida, December 19, 2005** – Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and IVAX Corporation (AMEX: IVX) issued the following statement regarding election procedures for holders of IVAX' outstanding convertible notes, in connection with Teva's pending acquisition of IVAX:

As previously announced, Teva and IVAX will permit holders of IVAX convertible notes who have not previously converted their notes to submit an election, upon conversion of the notes before the merger, with respect to the as yet undetermined amount of IVAX shares of common stock they would receive upon conversion, whether to receive their merger consideration in cash or Teva ADRs, subject to proration, in accordance with the terms of the merger agreement between the parties. Any such election instructions (referred to as "convert and tender" instructions) may be submitted by The Depository Trust Company ("DTC") participants through DTC's Automated Tender Offer Program ("ATOP"). Holders should contact their brokers for further instructions. Holders retain the option of not making an election and receiving IVAX common stock (or, if applicable, the merger consideration payable to non-electing shareholders) in accordance with the normal conversion procedures.

Any such "convert and tender" instruction, to be effective, must be made at least two business days prior to the closing date. Pursuant to the provisions of the applicable indentures, IVAX will provide at least 15 days notice of the anticipated closing date of the merger.

This announcement does not constitute a recommendation to the holders of IVAX convertible notes as to which action, if any, they may choose to take.

## **About Teva**

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe.

## **About IVAX**

IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S. and internationally.

### ***Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:***

*The statements, analyses and other information contained herein relating to the proposed merger and the contingencies and uncertainties to which Teva and IVAX may be subject, as well as other statements including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "should," "may" and other similar expressions, are "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Such statements are made based upon management's current expectations and beliefs concerning future events and their potential effects on the company.*

*Actual results may differ materially from the results anticipated in these forward-looking statements. Important factors that could cause or contribute to such differences include whether and when the proposed acquisition will be consummated and the terms of any conditions imposed in connection with such closing, including any required divestitures in connection with obtaining antitrust approvals, Teva's ability to rapidly integrate IVAX's operations and achieve expected synergies, diversion of management time on merger-related issues, Teva and IVAX's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products (so called "authorized generics") or successfully extend the exclusivity period of their branded products, the effects of competition on Copaxone<sup>®</sup> sales, regulatory changes that may prevent Teva or IVAX from exploiting exclusivity periods, potential liability for sales of generic products prior to completion of appellate litigation, including that relating to Neurontin<sup>®</sup> and Allegra<sup>®</sup>, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F, IVAX's Annual Report on Form 10-K and their other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and neither Teva nor IVAX undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.*

*This communication is being made in respect of the proposed merger involving Teva and IVAX. In connection with the proposed merger, Teva has filed a registration statement on Form F-4 containing a joint proxy statement/prospectus for the shareholders of Teva and IVAX with the SEC. **Before making any investment decision, holders of IVAX convertible notes, IVAX shareholders and other investors are urged to read the joint proxy statement/prospectus regarding the merger and any other relevant documents carefully in their entirety because they contain important information about the proposed transaction. The registration statement containing the joint proxy statement/prospectus and other documents are available free of charge at the SEC's website, [www.sec.gov](http://www.sec.gov). You may also obtain the joint proxy statement/prospectus and other documents free of charge by contacting IVAX Investor Relations at (305) 575-6000 or Teva Investor Relations at 972-3-926-7554.***



19 בדצמבר, 2005

## טבע ו-IVAX מודיעות על בחירה של מחזיקי אגרות חוב להמרה של IVAX

טבע ו-IVAX מודיעות על הליכי הבחירה של מחזיקי אג"ח להמרה של IVAX, בקשר לרכישת טבע את IVAX:

כפי שהודענו בעבר, טבע ו-IVAX יאפשרו למחזיקי האג"ח להמרה של IVAX אשר טרם המירו האג"ח, להודיע, למועד המרת האג"ח האמורות טרם המיזוג וזאת בהתייחס לכמות המניות של IVAX אשר טרם נקבעה אותה יקבלו כתוצאה מההמרה, אם ברצונם לקבל את התשלום במזומן או במניות טבע, בכפוף לחלוקה יחסית, בהתאם לתנאי הסכם המיזוג בין הצדדים. ניתן להגיש את הוראות הבחירה כאמור להלן ("convert and tender" instructions) באמצעות החברים במסלוקה - Depository Trust Company ("DTC") באמצעות Automated Tender Offer Program ("ATOP") של ה-DTC. על מחזיקי האג"ח ליצור קשר עם הברוקרים שלהם לקבלת הוראות נוספות. למחזיקי האג"ח הזכות לא לבצע בחירה ולקבל מניות IVAX (או בהתאם לנסיבות, את תמורת המיזוג אשר תשולם לבעלי המניות אשר לא ביצעו בחירה) בהתאם להליכי ההמרה הרגילים.

על מנת שהוראות "convert and tender" יהיו תקפות, עליהן להנתן לפחות שני ימי עבודה לפני תאריך סגירת העיסקה. בהתאם לקבוע בתנאי האג"ח, IVAX תודיע לפחות 15 ימים מראש על התאריך הצפוי לסגירת עסקת המיזוג.

אין לראות בהודעה המלצה כלשהי למחזיקי האג"חים להמרה של IVAX לביצוע כל פעולה, אם בכלל.

טבע תעשיות פרמצבטיות בע"מ הינה חברה גלובלית שבסיסה בישראל ואחת מ-20 החברות הפרמצבטיות המובילות בעולם. טבע, המתמחה בייצור תרופות גנריות וייחודיות ובייצור חומרים פעילים לתעשייה הפרמצבטית, הינה אחת מהמובילות בעולם בתחום הגנריקה. לטבע אתרי ייצור, מחקר, שיווק והפצה בישראל, בצפון ובמרכז אמריקה ובאירופה. קרוב ל-90% ממכירותיה של הקבוצה הן לצפון אמריקה ואירופה.

-----

להלן הסעיף הידוע בארה"ב כ- Safe Harbor בנוסחו האנגלי ואשר מטרתו להגן על החברה, עפ"י הדין האמריקאי:

*The statements, analyses and other information contained herein relating to the proposed merger and the contingencies and uncertainties to which Teva and IVAX may be subject, as well as other statements including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "should," "may" and other similar expressions, are "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Such statements are made based upon management's current expectations and beliefs concerning future events and their potential effects on the company.*

*Actual results may differ materially from the results anticipated in these forward-looking statements. Important factors that could cause or contribute to such differences include whether and when the proposed acquisition will be consummated and the terms of any conditions imposed in connection with such closing, including any required divestitures in connection with obtaining antitrust approvals, Teva's ability to rapidly integrate IVAX's operations and achieve expected synergies, diversion of management time on merger-related issues, Teva and IVAX's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products (so called "authorized generics") or successfully extend the exclusivity period of their branded products, the effects of competition on Copaxone<sup>®</sup> sales, regulatory changes that may prevent Teva or IVAX from exploiting exclusivity periods, potential liability for sales of generic products prior to completion of appellate litigation, including that relating to Neurontin<sup>®</sup> and Allegra<sup>®</sup>, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F, IVAX's Annual Report on Form 10-K and their other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and neither Teva nor IVAX undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.*

*This communication is being made in respect of the proposed merger involving Teva and IVAX. In connection with the proposed merger, Teva has filed a registration statement on Form F-4 containing a joint proxy statement/prospectus for the shareholders of Teva and IVAX with the SEC. Before making any investment decision, holders of IVAX convertible notes, IVAX shareholders and other investors are urged to read the joint proxy*

קשורי משקיעים [liraz.kalif@teva.co.il](mailto:liraz.kalif@teva.co.il)

רח' בול 5 ת.ד. 3190 פתח-תקוה 49131 טל. 03-9267281 פקסימייל 03-9267519

Web site: [www.tevapharm.com](http://www.tevapharm.com)



*statement/prospectus regarding the merger and any other relevant documents carefully in their entirety because they contain important information about the proposed transaction. The registration statement containing the joint proxy statement/prospectus and other documents are available free of charge at the SEC's website, [www.sec.gov](http://www.sec.gov). You may also obtain the joint proxy statement/prospectus and other documents free of charge by contacting IVAX Investor Relations at (305) 575-6000 or Teva Investor Relations at 972-3-926-7554.*

קשרי משקיעים [liraz.kalif@teva.co.il](mailto:liraz.kalif@teva.co.il)  
רח' בול 5 ת.ד. 3190 פתח-תקוה 49131 טל. 03-9267281 פקסימיליה 03-9267519

Web site: [www.tevapharm.com](http://www.tevapharm.com)